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Treatment strategies against corona virus disease 
(COVID)-19 have been investigated since the recognition 
of SARS-CoV-2. Anti-viral strategies such as Remdesivir 
have shown effects in the early disease phase [1]. Pro-
gression is often driven by a dysregulated host response 
triggering a hyper-inflammatory phenotype. In this state, 
anti-infectives were inferior to anti-inflammatory strate-
gies. Dexamethasone improves survival in COVID-19 
patients with pneumonia requiring oxygen [2]. Tocili-
zumab—a humanized anti-human IL-6 receptor (IL-6R) 
antibody of the IgG1 subclass—has gained attention due 
to a potential synergistic survival benefit [3], especially 
in certain subpopulations. Tocilizumab is no stranger to 
rheumatologists as it has widely been used to treat vari-
ous disorders such as rheumatoid arthritis.
Although some intensivists had experience with Toci-
lizumab to control CAR-T-associated cytokine release 
syndrome (CRS), it remains an alien in the intensivists’ 
armamentarium. Still, many colleagues have adopted this 
drug in light of the recent data to treat severe COVID-
19. Given its unknown biological specifics in the critical 
care context, we have analyzed the longitudinal course 
of IL-6, together with C-reactive protein (CRP), proc-
alcitonin (PCT) and leucocyte counts in 16 COVID-19 
patients (Fig.  1). Baseline characteristics and outcomes 
are demonstrated in Table  1. Tocilizumab was almost 
exclusively administered if there was a progression of 
the disease (i.e., requirement of invasive ventilation in 
those on high-flow oxygen or deterioration in invasively 
ventilated patients) despite prior steroid use. Aside from 
reported side effects [3], we want to highlight the follow-
ing phenomena:
1. Increase in IL-6 Circulating IL-6 serum levels 
increase rapidly and profoundly (up to 38×), peak 
around day 3–5 and stay elevated for many days after 
Tocilizumab administration. Comparable increases 
have also been described in other studies [4].
2. Suppression of CRP In line with the previous litera-
ture [4], IL-6R blockade leads to a sustained suppres-
sion of downstream effectors such as CRP. In our 
cohort, this effect was observed for approximately 
14  days rendering its clinical use as a biomarker of 
infection useless (“CRP-blind spot”).
3. Unchanged leucocyte count and PCT Despite their 
limited sensitivity and specificity, leukocyte count 
and PCT are rather unaffected by Tocilizumab and 
might give additional information during the “CRP-
blind spot”. However, the relevance of these phenom-
ena has still not been elucidated in COVID-19 and 
should be seen in an individual context.
Additionally, we want to highlight two aspects that are of 
importance when administering Tocilizumab:
4. Increased infection risk Blockade of the IL-6R 
increases the risk of serious infections and should not 
be used in sepsis. Bacterial, viral and opportunistic 
infections have been reported [5].
5. Development/aggravation of encephalopathy Due 
to its pharmacodynamics, Tocilizumab is unable 
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to cross the blood–brain-barrier but increases 
the circulating amount of IL-6 (a small molecule 
that can easily do so) up to 3800%. This phenom-
enon of induced encephalopathy is known from 
CAR-T-associated CRS and should be considered 
when giving Tocilizumab to awake patients (par-
ticularly in the context of delirium) [6]. Whereas it 
has been used in the CAR-T context according to 
the standard algorithm usually before steroids, in 
COVID-19, Tocilizumab’s effect might be different 
after prior steroid use.Mechanistically, it has been 
proposed that the increase in IL-6 is the result of 
IL-6R blockade, inhibiting internalization of IL-6 
after ligation with its receptor. In other words, 
the blocked IL-6R liberates the release of accu-
mulated IL-6 into the circulation. One can spec-
ulate that a given IL-6 increase reflects its local 
production in the inflamed lung and that this 
increase might even be useful to predict a clinical 
Tocilizumab response. In our rather small cohort, 
no differences between survivors and non-survi-
Fig. 1 Longitudinal course over 20 days after Tocilizumab administration in 16 critically ill COVID-19 patients (local ethical approval: 2020-00646). 
Box and whiskers blots together with colored area demonstrate circulating levels of a Interleukin (IL)-6, b C-reactive protein (CRP), c procalcitonin 
(PCT) and d leucocytes. Days 0 = Tocilizumab administration (8 mg/kg bodyweight, max: 800 mg)
Table 1 Baseline characteristics and outcome of 16 critically ill 
COVID-19 patients
Results provided as absolute numbers and (percentages) or as median, 
[interquartile range] and (95% confidence interval), as appropriate
BMI body mass index, CAD coronary artery disease, COPD chronic obstructive 
pulmonary disease, SOFA score sequential organ failure assessment score, ICU; 
intensive care unit
Age (years) 55.5 [47–63] (48–63)
BMI (kg/m2) 30.5 [26–33] (27–32)
Male gender 7/16 (43.8%)
Comorbidities
Arterial hypertension 5/16 (31.3%)
CAD 1/16 (6.3%)
COPD 1/16 (6.3%)
Diabetes mellitus 4/16 (25%)
Chronic kidney disease 3/16 (18.8%)
SOFA score at ICU admission 11 [06–12] (11–12)
Invasive mechanical ventilation 13/16 (81.3%)
ICU survival 9/16 (56.3%)
Length of ICU stay (d) 26 [18–31] (19–32)
Steroids before Tocilizumab administration 13/16 (81.3%)
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